other

Updated:

Viatris Inc.

Viatris Inc. is a publicly traded global healthcare company headquartered in Canonsburg, Pennsylvania, focused on accessible medicines and supply resilience.

Viatris Inc.

At Viatris, we empower people worldwide to live healthier at every stage of life.

General information

Firm type

other

Location

Region

North America

Country

United States

City

Canonsburg

Corporate office

Canonsburg, PA, United States

Sector focus

Healthcare Services

Frequently asked questions

Is Viatris a family office or an investment firm?

No. Viatris is a publicly traded pharmaceutical company (NASDAQ: VTRS), not a family office. It manufactures and sells prescription drugs, generics, and over-the-counter products.

Who leads Viatris?

Viatris is managed by a CEO and executive team, accountable to its board of directors. The firm's public filings name its leadership, which changes periodically. As of mid-2026, its website does not list a permanent dedicated leadership page.

What is Viatris's business model?

Viatris develops, manufactures, and distributes medicines across a broad range of therapeutic areas. It operates both branded and generic product lines, with a focus on affordability and global supply resilience.

Does Viatris manage assets on behalf of external investors?

No. Viatris does not operate as an asset manager or investment vehicle. Its revenues come from product sales, not from managing third-party capital.

Where is Viatris headquartered?

Viatris's headquarters are in Canonsburg, Pennsylvania, United States. It has additional operational sites and manufacturing facilities globally.

What is Viatris's relationship to Mylan and Pfizer?

Viatris was created in 2020 from the merger of Mylan and Upjohn (a division of Pfizer). Pfizer spun off the Upjohn business to combine with Mylan, forming Viatris.

Is Viatris publicly traded?

Yes. Viatris trades on the NASDAQ under the ticker VTRS. As a public company, its financial disclosures are available via SEC filings.

Profile maintained by using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.

Need institutional-grade insight on investors?

Altss delivers:

Principals with verified direct contactsAllocation history by asset classOSINT-derived deal signals
Book a demo

Prefer a guided tour?

We’ll walk you through:

Interactive funding timelinesCustom mandate & allocation filters
Book a demo

More Canonsburg other profiles